SCHEMBL21821572

SCHEMBL21821572

O=C1CC(c2ccc(Sc3ccccc3)cc2)CC(=O)C1=CNCCN1CCN(CCO)CC1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC18A3 Q16572 1/20 0.41
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ CYP2C19 P33261 2/20 0.36
▸ MAP1LC3B Q9GZQ8 8/20 0.36
▸ USP2 O75604 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CARM1 Q86X55 1/20 0.34
▸ PRMT6 Q96LA8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21821591 0.90 SLC18A3 (0.50) SLC18A3MEN1KMT2ACYP2C19MAP1LC3B
SCHEMBL26523519 0.88 ALDH1A1 (0.43) SLC18A3MEN1KMT2ACYP2C19MAP1LC3B
SCHEMBL21821781 0.85 ALDH1A1 (0.38) SLC18A3MEN1KMT2AMAP1LC3BUSP2
SCHEMBL21821754 0.84 MAP1LC3B (0.44) SLC18A3MEN1KMT2AMAP1LC3BUSP2
SCHEMBL21821814 0.84 MAP1LC3B (0.45) SLC18A3MEN1KMT2ACYP2C19MAP1LC3B
SCHEMBL26523529 0.83 ALDH1A1 (0.37) SLC18A3MEN1KMT2ACYP2C19MAP1LC3B
SCHEMBL21821626 0.82 MAPK11 (0.38) SLC18A3MEN1KMT2AMAP1LC3BALDH1A1
SCHEMBL22111740 0.82 CYP3A4 (0.37) SLC18A3MEN1KMT2AHTTALDH1A1
SCHEMBL26523405 0.82 MEN1 (0.48) MEN1KMT2ACYP2C19MAP1LC3BCARM1
SCHEMBL21821839 0.81 KDM1A (0.37) SLC18A3MEN1KMT2AMAP1LC3BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632903-B1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) 2023-10-11 — — EP disclosed
EP-3632903-B1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) 2023-10-11 — — EP disclosed
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2022-05-03 — — US disclosed
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2022-05-03 — — US disclosed
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2020-06-18 — — US disclosed
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2020-06-18 — — US disclosed
EP-3632903-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2020-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof ATG7, SQSTM1, BECN1 SLC18A3 2277/4885MEN1 3447/4885KMT2A 3378/4885
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF ATG7, SQSTM1, BECN1 SLC18A3 2277/4885MEN1 3447/4885KMT2A 3378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback